Dr. Gerard van Odijk

Chair

Drs. Gerard WM van Odijk has an over 25 years track record in the health care industry. From 2006 until the middle of 2012 he has served as President and CEO of Teva Pharmaceuticals Europe. In which role he has been deeply involved in the many successful acquisitions of Teva. He obtained his medical degree from Utrecht University. Following his academic degree, he has held various international executive position and a senior position in GlaxoSmithKline (GSK). Since 2013 he is an independent healthcare industrial advisor. Gerard currently serves as Chairman of the Board for Bavarian Nordic A/S.  He also is Chairman of the Board of Curaeos bv and until recently  Chairman of HTL-Strefa S.A. Before this Gerard has been chairman of Merus n.v. and Syntarga bv. He also served as Non-Executive Board member on the Board of UDG Healthcare plc, Neurogen A/S  and Alvogen Sárl. He is member of the advisory board of the Dutch Medicine Agency.

October 21, 2020 Webinar: Drug Discovery Powered by HUB Organo... Drug Discovery Powered by HUB Organoids and OcellO 3D Image Analysis Summary: More clinically relevant models are urgent... read more
September 04, 2020 HUB and BGI-Qingdao sign a Memorandum of Unde... Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced today that they ... read more
May 27, 2020 Studying the development of ovarian cancer wi... read more